Table 1.
Demographic and clinical features of EBLs, NEBLs and NEBLs*
| Variable | EBLs (n=16) | NEBLs (n=53) | NEBLs* (n=37) | P 1 | P2 |
|---|---|---|---|---|---|
| Age at symptom onset (years) |
33.0±1.55 |
32.8±1.42 |
35.3±1.42 |
NS |
NS |
| Sex(Male/Female) |
2/14 |
7/46 |
4/33 |
NS |
NS |
| Annualized relapse rate |
2.11 ± 2.0 |
1.17 ± 0.6 |
1.10 ± 1.15 |
NS |
NS |
| Relapse times |
5(3–18) |
5(2–16) |
5(2–16) |
NS |
NS |
| Duration (months) |
82.4±5.2 |
83.5±6.0 |
99.3±6.34 |
NS |
NS |
| Brain symptom(%) |
10(62.5%) |
27(50.1%) |
20(54.1%) |
NS |
NS |
| encephalopathy symptom |
6(37.5%) |
3(5.6%) |
3(8.1%) |
0.004 |
0.016 |
| brain-stem symptom |
5(31.2%) |
20(37.7%) |
13(35.1%) |
NS |
NS |
| cerebellum involvement |
2(12.5%) |
4(7.5%) |
3(8.1%) |
NS |
NS |
| homonymous hemianopia |
3(18.8%) |
0(0) |
0(0) |
0.011 |
0.024 |
| EDSS* |
2.49 ± 1.03 |
1.98± 0.97 |
2.00 ± 1.04 |
NS |
NS |
| EDSS** |
7.67 ± 1.48 |
5.32 ± 1.82 |
5.32 ± 1.82 |
0.000 |
0.000 |
| Serum Analysis |
|
|
|
|
|
| CRP (mg/l) |
12.32 ± 3.05 |
2.65 ± 0.61 |
3.01 ± 1.01 |
0.000 |
0.000 |
| ESR (mm/H) |
27.67 ± 16.49 |
15.83 ± 11.28 |
15.24 ± 12.24 |
0.005 |
0.004 |
| C3 (g/l) |
1.42 ± 0.50 |
1.15 ± 0.27 |
1.14 ± 0.30 |
0.049 |
0.043 |
| C4 (g/l) |
0.29 ± 0.16 |
0.22 ± 0.09 |
0.22 ± 0.07 |
0.046 |
NS |
| CH50 (U/ml) |
50.73 ± 10.62 |
45.96 ± 11.32 |
44.43 ± 11.52 |
NS |
NS |
| AQP4 seropositivity |
16(100%) |
37(69.8%) |
37(100%) |
0.008 |
|
| CSF Analysis |
|
|
|
|
|
| CSF-TP (mg/ml) |
0.41 ± 0.25 |
0.29 ± 0.17 |
0.31 ± 0.18 |
NS |
NS |
| CSF-WBC (10) |
6.0(0–58) |
5(0–98) |
5(0–46) |
NS |
NS |
| CSF-OCB | 1(6.25%) | 3(5.66%) | 2(5.40%) | NS | NS |
EBLs neuromyelitis optica with extensive brain lesions; NEBLs=neuromyelitis optica without extensive brain lesions; NEBLs*=neuromyelitis optica without extensive brain lesions and with a positive Anti-AQP4; EDSS Expanded Disability Status Scale; NS no significant; EDSS* 6 months before EBLs presentation or clinical onset; EDSS** at EBLs presentation or clinical onset; AQP4 aquaporin-4; CSF cerebrospinal fluid, CSF taken during EBLs presentation or clinical onset; P1=EBLs vs NEBLs; P2=EBLs vs NEBLs*.